The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

Healthcare System Resilience and Adaptation: A 6-Year Analysis of Heart Failure Care in the Veterans Affairs System

Brownell NK, Inkelas M, Chen L, Leng M, Doan AAQ, Shannon E, Jackson N, Hsue P, Ong M, Yano E, Fonarow GC, Ziaeian B. Healthcare[...]

Correction: Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease

Greb AC, Kim S, Roney A, Ting PS, Limketkai BN, Chen PH. Correction: Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver[...]

Symptom Burden After Dialysis Initiation and Its Association With Hospitalization

Nair D, Cai X, Hays RD, Aiyegbusi OL, Frazier RS, Isakova T, Peipert JD. Symptom Burden After Dialysis Initiation and Its Association With Hospitalization. Kidney[...]